We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Team Designs Molecule That Inhibits the Replication of Coronaviruses
News

Team Designs Molecule That Inhibits the Replication of Coronaviruses

Team Designs Molecule That Inhibits the Replication of Coronaviruses
News

Team Designs Molecule That Inhibits the Replication of Coronaviruses

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Team Designs Molecule That Inhibits the Replication of Coronaviruses"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The new coronavirus has caused more than five million deaths. Many lives could have been saved with antiviral drugs, but no treatment of this type has been available to the healthcare system. During the pandemic, researchers around the world have tried to find a pharmaceutical, but the development of new medications often takes a long time.


During the first months of the pandemic, researchers were able to determine the structure of the coronavirus and how it functions at the molecular level. One of the viral enzymes was identified as a promising target for a drug, which is a strategy that has been successful for other viral diseases, such as AIDS. The idea is to design a molecule with the ability to recognise and bind to the enzyme. This would block its activity and thereby prevent the virus from producing new virus particles, stopping the spread of the virus.


In 2020, researchers at Uppsala University, in collaboration with the Drug discovery and Development platform at Scilifelab, began to screen for inhibitors of the enzyme. They used computer models to identify molecules that can inhibit the enzyme’s activity. This proved to be a fast way to discover starting points for the design of pharmaceuticals. Access to Swedish supercomputers has made it possible to evaluate several hundred million different molecules to find those that can bind to the enzyme. The molecules predicted by the models were then synthesised and tested in experiments.


“The most promising molecule shows the same ability to inhibit the replication of the new coronavirus as the active substance in Paxlovid, a combination drug recently approved for treating COVID-19. Our molecule works well on its own, and we have shown that the molecule is also effective against previously identified variants of the coronavirus”, says Jens Carlsson, associate professor and the article’s lead author.


Reference: Luttens A, Gullberg H, Abdurakhmanov E, et al. Ultralarge Virtual screening identifies SARS-CoV-2 main protease inhibitors with broad-spectrum activity against coronaviruses. J Am Chem Soc. 2022. doi: 10.1021/jacs.1c08402


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement